The Ministry of Chemicals and Fertilizers on July 22, 2022, issued a notification regarding the ceiling price of all scheduled formulations specified in the first schedule of the Drugs (Prices Control) Order, 2013 (DPCO) which specifies the “National List of Essential Medicines 2015”. All manufacturers of scheduled medicines have to sell their products within the ceiling price fixed by the National Pharmaceutical Pricing Authority (NPPA).
The National Pharmaceutical Pricing Authority (NPPA) fixes the retail price of new drugs under the Drugs (Prices Control) Order, 2013 (DPCO) for existing manufacturers of scheduled formulations. In respect of non-scheduled formulations, a manufacturer is at liberty to fix its Maximum Retail Price (MRP) but cannot increase the same by more than 10% of what was prevalent during the preceding 12 months.
The following have been brought under price control/ regulation by NPPA:
• Ceiling prices of 890 scheduled formulations across various therapeutic categories under NLEM 2015 have been fixed by NPPA.
• Retail price of approx. 2,023 new drugs under DPCO, 2013 have been fixed.
• MRP of 106 non-scheduled drug formulations capped, including that for 22 diabetic and 84 cardiovascular drugs.
• Ceiling price of Orthopaedic Knee Implants fixed under Para 19 of DPCO, 2013.
• Trade Margin of non-scheduled formulations of 42 select Anti-cancer medicines capped under ‘Trade Margin Rationalization’ approach as a pilot for proof of concept.
• Regulated the price of Oxygen Concentrators, Pulse Oximeter, Blood Pressure Monitoring Machine, Nebulizer, Digital Thermometer and Glucometer under ‘Trade Margin Rationalisation’ Approach.
The details of ceiling prices and retail prices of various formulations fixed by NPPA are available at its website at nppaindia.nic.in.
[Release ID: 1843838]
